Citigroup’s Moleculin Biotech MBRX Stock Holding History

Citigroup’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,411	Closed	-$25.7K	–	6227
2025 Q2	$25.7K	Buy	3,411 +3,299	+2,946%	+$67.6K	﹤0.01%	5018
2025 Q1	$2.71K	Buy	+112	New	+$3.76K	﹤0.01%	5330
2017 Q1	–	Sell	-3	Closed	-$17K	–	7270
2016 Q4	$17K	Buy	3 +1	+50%	+$6.7K	﹤0.01%	6592
2016 Q3	$29K	Hold	2	–	–	﹤0.01%	6007
2016 Q2	$33K	Buy	+2	New	+$32.3K	﹤0.01%	5836

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

WDG

Wealth Dimensions Group Cincinnati, Ohio $508M AUM 15.32% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's MBRX Position: Q3 2025 in Review

Citigroup sold out of Moleculin Biotech (MBRX) in Q3 2025, closing a stake of 3,411 shares — an estimated $25.7K sold.

Citigroup first reported a position in MBRX in Q2 2016 and held it in 5 quarters. The position peaked at $33K in Q2 2016. 24 funds tracked by Wall St. Rank hold MBRX as of Q3 2025.

Citigroup reported no remaining Moleculin Biotech position as of Q3 2025 after selling out during the quarter.
Citigroup sold 3,411 Moleculin Biotech shares in Q3 2025, an estimated $25.7K.
Citigroup first reported a position in Moleculin Biotech in Q2 2016 and held it in 5 quarters.
Citigroup's Moleculin Biotech position peaked at $33K in Q2 2016.
24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.